These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

626 related articles for article (PubMed ID: 28986384)

  • 1. Mass spectrometry for fragment screening.
    Chan DS; Whitehouse AJ; Coyne AG; Abell C
    Essays Biochem; 2017 Nov; 61(5):465-473. PubMed ID: 28986384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A three-stage biophysical screening cascade for fragment-based drug discovery.
    Mashalidis EH; Śledź P; Lang S; Abell C
    Nat Protoc; 2013 Nov; 8(11):2309-24. PubMed ID: 24157549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biophysical screening for the discovery of small-molecule ligands.
    Ciulli A
    Methods Mol Biol; 2013; 1008():357-88. PubMed ID: 23729259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fragment-based drug discovery and its application to challenging drug targets.
    Price AJ; Howard S; Cons BD
    Essays Biochem; 2017 Nov; 61(5):475-484. PubMed ID: 29118094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The SGC beyond structural genomics: redefining the role of 3D structures by coupling genomic stratification with fragment-based discovery.
    Bradley AR; Echalier A; Fairhead M; Strain-Damerell C; Brennan P; Bullock AN; Burgess-Brown NA; Carpenter EP; Gileadi O; Marsden BD; Lee WH; Yue W; Bountra C; von Delft F
    Essays Biochem; 2017 Nov; 61(5):495-503. PubMed ID: 29118096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experiences in fragment-based lead discovery.
    Hubbard RE; Murray JB
    Methods Enzymol; 2011; 493():509-31. PubMed ID: 21371604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NMR in structure-based drug design.
    Carneiro MG; Ab E; Theisgen S; Siegal G
    Essays Biochem; 2017 Nov; 61(5):485-493. PubMed ID: 29118095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establish an automated flow injection ESI-MS method for the screening of fragment based libraries: Application to Hsp90.
    Riccardi Sirtori F; Caronni D; Colombo M; Dalvit C; Paolucci M; Regazzoni L; Visco C; Fogliatto G
    Eur J Pharm Sci; 2015 Aug; 76():83-94. PubMed ID: 25952103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Counting on Fragment Based Drug Design Approach for Drug Discovery.
    Kashyap A; Singh PK; Silakari O
    Curr Top Med Chem; 2018; 18(27):2284-2293. PubMed ID: 30499406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HTS by NMR of combinatorial libraries: a fragment-based approach to ligand discovery.
    Wu B; Zhang Z; Noberini R; Barile E; Giulianotti M; Pinilla C; Houghten RA; Pasquale EB; Pellecchia M
    Chem Biol; 2013 Jan; 20(1):19-33. PubMed ID: 23352136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Native Mass Spectrometry in Fragment-Based Drug Discovery.
    Pedro L; Quinn RJ
    Molecules; 2016 Jul; 21(8):. PubMed ID: 27483215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-Throughput Screening by Nuclear Magnetic Resonance (HTS by NMR) for the Identification of PPIs Antagonists.
    Wu B; Barile E; De SK; Wei J; Purves A; Pellecchia M
    Curr Top Med Chem; 2015; 15(20):2032-42. PubMed ID: 25986689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applications of Biophysics in High-Throughput Screening Hit Validation.
    Genick CC; Barlier D; Monna D; Brunner R; Bé C; Scheufler C; Ottl J
    J Biomol Screen; 2014 Jun; 19(5):707-14. PubMed ID: 24695619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experimental free ligand conformations: a missing link in structure-based drug discovery.
    Chiarparin E; Packer MJ; Wilson DM
    Future Med Chem; 2019 Jan; 11(2):79-82. PubMed ID: 30648432
    [No Abstract]   [Full Text] [Related]  

  • 15. Hit-to-Lead: Hit Validation and Assessment.
    Hevener KE; Pesavento R; Ren J; Lee H; Ratia K; Johnson ME
    Methods Enzymol; 2018; 610():265-309. PubMed ID: 30390802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Native MS: an 'ESI' way to support structure- and fragment-based drug discovery.
    Vivat Hannah V; Atmanene C; Zeyer D; Van Dorsselaer A; Sanglier-Cianférani S
    Future Med Chem; 2010 Jan; 2(1):35-50. PubMed ID: 21426045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fragment-based lead discovery and design.
    Joseph-McCarthy D; Campbell AJ; Kern G; Moustakas D
    J Chem Inf Model; 2014 Mar; 54(3):693-704. PubMed ID: 24490951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated biophysical approach to fragment screening and validation for fragment-based lead discovery.
    Silvestre HL; Blundell TL; Abell C; Ciulli A
    Proc Natl Acad Sci U S A; 2013 Aug; 110(32):12984-9. PubMed ID: 23872845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fragment screening using X-ray crystallography.
    Davies TG; Tickle IJ
    Top Curr Chem; 2012; 317():33-59. PubMed ID: 21678136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fragment-Based Ligand Designing.
    Katiyar SP; Malik V; Kumari A; Singh K; Sundar D
    Methods Mol Biol; 2018; 1762():123-144. PubMed ID: 29594771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.